|
Q-401
|
Thursday, October 2, 2025 |
With regard to the 2021 recommendation of the Veterans Ombud to the government concerning mental health treatment benefits for family members of veterans in their own right for the conditions related to military service, in which the Ombud recommended government funded mental health treatment independent of the veteran’s treatment plan and regardless of whether the veteran is engaging in treatment: (a) does it remain the position of the government that it accepts this recommendation, and, if not, when the did the position change; (b) what is the government’s current progress in implementing this recommendation; (c) what tangible steps have been taken to implement this recommendation, and on what date was each step taken; (d) how many times, and through which methods, has the government communicated with the Veterans Ombud or her office concerning the implementation of this recommendation, and on what dates did the communications occur; and (e) how many times has the Department of Veterans Affairs communicated with or received communication from other government departments or agencies related to the recommendation, and what are the details of each communication, including (i) the date, (ii) who was involved, (iii) the type of communication, (iv) a summary of what was communicated? |
Answered |
Wednesday, November 19, 2025 |
|
Q-345
|
Friday, September 19, 2025 |
With regard to medical assistance in dying and Veterans Affairs Canada, since September 2022: (a) how many times has a (i) Veterans Affairs Canada employee, (ii) third-party contracted by Veterans Affairs Canada, advised, suggested, or discussed medical assistance in dying with a veteran; (b) what is Veterans Affairs Canada's current policy regarding its (i) employees, (ii) contractors, suggesting medical assistance in dying to veterans; and (c) on what date did the policy in (b) come into effect? |
Answered |
Wednesday, November 5, 2025 |
|
Q-340
|
Thursday, September 18, 2025 |
With regard to Health Canada and Public Health Agency of Canada messaging about the safety of COVID-19 vaccines during pregnancy and lactation and website messaging that reads, “Vaccination is an important part of a healthy pregnancy, with health benefits for both the pregnant person and their baby. Several vaccines are routinely recommended during pregnancy, including COVID-19 vaccines [...] Evidence suggests that COVID-19 vaccination during pregnancy helps to prevent: COVID-19 infection and the risk of hospitalization from COVID-19 in infants under 6 months of age” and the government response to Order Paper Question Q-2163 from the 44th Parliament, which reads, “As indicated in the specific Product Monographs, it is noted that the safety and efficacy of these vaccines in pregnant women have not yet been established. No indication for use in pregnant or lactating women was sought by the vaccine sponsors or authorized by Health Canada [...] Health Canada has not approved any safety claims with regard to pregnant and lactating women”: (a) how does Health Canada and the Public Health Agency of Canada explain these two conflicting statements; (b) who wrote the statement on the government's website and who approved it; and (c) who wrote the statement in the response to Q-2163 and who approved it? |
Answered |
Wednesday, November 5, 2025 |
|
Q-218
|
Tuesday, June 17, 2025 |
With regard to the recommendations in Health Canada’s publication through the National Advisory Committee on Immunization titled, “Vaccination and pregnancy: COVID-19”: (a) how do these recommendations differ from the May 27, 2025, announcement by the United States of America’s Health and Human Services, stating the COVID-19 vaccine would no longer be included in the Centers for Disease Control and Prevention’s recommended immunization schedule for healthy pregnant women and healthy children (herein referred to as “cohort”) citing “mixed data” on booster safety and efficacy for pregnant women while seeking stricter clinical trials for vaccine approvals in healthy individuals under 65; (b) did communications occur, related to the Health and Human Services announcement, between Health Canada, the National Advisory Committee on Immunization or the Public Health Agency of Canada and (i) Health and Human Services, (ii) the United States of America’s Food and Drug Administration, (iii) the United States’Centers for Disease Control and Prevention, (iv) the United Kingdom’s Medicines & Healthcare products Regulatory Agency, (v) the European Medical Agency; (c) if the answer to (b) is affirmative, what (i) were the dates of the communications, (ii) were the modes of communications, (iii) were the names and titles of people included in the communications, (iv) was the outcome; (d) to Health Canada's knowledge, did the Medicines & Healthcare products Regulatory Agency or the European Medical Agency agree with Health Canada’s recommendations for the administration of the COVID-19 vaccine to this cohort; (e) does Health Canada, the National Advisory Committee on Immunization or the Public Health Agency of Canada have mixed data regarding booster safety and efficacy of the COVID-19 vaccine in this cohort, and, if so, how does this impact the risk-benefit analysis; (f) is Health Canada , the Public Health Agency of Canada or the National Advisory Committee on Immunization including the same or different data than the United States of America’s Health and Human Services, Food and Drug Administration, and Centers for Disease Control and Prevention in the decision to continue recommending the COVID-19 vaccines for this cohort; (g) what clinical trials or data is Health Canada, the National Advisory Committee on Immunization and the Public Health Agency of Canada including in their decision that gives them confidence to continue recommending these vaccines that differs from the United States of America’s Health and Human Services, the Food and Drug Administration, and the Centers for Disease Control and Prevention; (h) is Health Canada planning to request stricter clinical trials for vaccine approvals in healthy individuals under 65 in the future, and, if not, why not; (i) if the answer to (h) is affirmative, what additional vaccine clinical trial requirements will be needed for approval; (j) are there plans to change the recommendations with respect to the COVID-19 vaccine in this cohort; and (k) if the answer to (j) is affirmative, when will these recommendations be announced, and what will they include? |
Answered |
Monday, September 15, 2025 |
|
Q-175
|
Thursday, June 12, 2025 |
With regard to the findings of the United Nations Committee on the Rights of Persons with Disabilities with respect to Canada's implementation of the Convention on the Rights of Persons with Disabilities: (a) what is the position of the government regarding these findings; (b) is the government considering changing any previous policies or positions in response to this report; (c) is the government considering repealing or making changes, in particular to Track 2 Medical Assistance in Dying, in response to this report, and, if so, what is the government considering repealing or changing; and (d) what are the government's legal obligations in light of the findings of the committee, in light of the fact that Canada is a signatory to the Convention on the Rights of Persons with Disabilities? |
Answered |
Monday, September 15, 2025 |
|
Q-163
|
Thursday, June 12, 2025 |
With regard to communications sponsored by the government during the COVID-19 pandemic: (a) which individual or agency developed the “Pregnancy, childbirth and caring for a newborn during the COVID-19 pandemic” communication, which was first published on July 13, 2021, and last updated on October 25, 2023; (b) who provided the final approval of the communication in (a) and when; (c) which individual or agency developed the narrative for the video titled, “Are there any ingredients in the COVID-19 vaccines that I should be concerned about”, narrated by Dr. Ayesha Raza; (d) who provided the final approval of the communication in (c) and when; (e) which individual or agency developed the narrative for the video titled, “Can the COVID-19 vaccines affect fertility”, narrated by Dr. Darine El-Chaâr; (f) who provided the final approval of the communication in (e) and when; (g) on December 23, 2021, which individual or agency developed the advice to Canadians about the interchangeability of vaccines found on the government's website, titled, “COVID-19 vaccine: Canadian Immunization Guide, For health professionals, Notice”; and (h) who provided the final approval of the communication in (g) and when? |
Answered |
Monday, September 15, 2025 |
|
Q-158
|
Wednesday, June 11, 2025 |
With regard to Veterans Affairs Canada’s public and private directives to veterans concerning the certification of service dogs: (a) what are the directives currently issued; (b) how has each directive changed between January 1, 2016, and today; and (c) from January 1, 2016, to today, what are the details of any internal or external communications or briefing materials between Veterans Affairs Canada officials or with other departments, stakeholders, or individuals relating to the public and private directives issued to veterans regarding the certification of service dogs, including the (i) date, (ii) title, (iii) sender, (iv) recipient, (v) type of communication, (vi) file or tracking number? |
Answered |
Monday, September 15, 2025 |
